In addition, miR-451a has been shown to act as a potential therapeutic agent in cancer treatment by targeting the tuberous sclerosis 1 (TSC1) gene, which activates the PI3K/Akt/mTOR signalling pathway in cancer cells. This evidence concerns the gene MTOR and cancer.